Cargando…

Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis

Detalles Bibliográficos
Autores principales:	Weyer, Karin, Falzon, Dennis, Jaramillo, Ernesto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	World Health Organization 2018
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239000/ https://www.ncbi.nlm.nih.gov/pubmed/30455511 http://dx.doi.org/10.2471/BLT.18.223230

Ejemplares similares

Drug-resistant tuberculosis: Progress towards shorter and safer regimens
por: Saravu, Kavitha, et al.
Publicado: (2019)

Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis
por: Patankar, Sayalee, et al.
Publicado: (2023)

World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
por: Falzon, Dennis, et al.
Publicado: (2017)

The Role of Novel Approaches and New Findings in the Pharmacology of Tuberculosis Medicines in Improving Treatment Outcomes
por: Falzon, Dennis, et al.
Publicado: (2018)

Rapid diagnosis and shorter regimen for multidrug-resistant tuberculosis: A priority to improve treatment outcome
por: Prasad, Rajendra, et al.
Publicado: (2017)

Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies
por: Hwang, Thomas J, et al.
Publicado: (2014)

Multidrug-resistant tuberculosis around the world: what progress has been made?
por: Falzon, Dennis, et al.
Publicado: (2015)

Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen
por: Lempens, Pauline, et al.
Publicado: (2020)

Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes
por: Decroo, Tom, et al.
Publicado: (2020)

Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019–2020
por: Avaliani, Teona, et al.
Publicado: (2021)

Moxifloxacin concentration correlate with QTc interval in rifampicin-resistant tuberculosis patients on shorter treatment regimens
por: Kusmiati, Tutik, et al.
Publicado: (2022)

Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope
por: Prasad, Rajendra, et al.
Publicado: (2017)

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan
por: du Cros, Philipp, et al.
Publicado: (2021)

Cost Effectiveness of a Shorter Moxifloxacin Based Regimen for Treating Drug Sensitive Tuberculosis in India
por: Muniyandi, Malaisamy, et al.
Publicado: (2022)

Effectiveness and Safety of a Shorter Treatment Regimen in a Setting with a High Burden of Multidrug-Resistant Tuberculosis
por: Trubnikov, Aleksandr, et al.
Publicado: (2021)

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan
por: Kohler, Stefan, et al.
Publicado: (2022)

Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2020)

Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan
por: Kohler, Stefan, et al.
Publicado: (2022)

Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens
por: Park, Hae-Young, et al.
Publicado: (2023)

Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
por: Singh, Pravin K., et al.
Publicado: (2019)

Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis
por: Tack, Ilse, et al.
Publicado: (2020)

Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country
por: Wahid, Abdul, et al.
Publicado: (2022)

Shorter TB treatment regimens should be safer as well
por: Rucsineanu, O., et al.
Publicado: (2023)

Pharmacovigilance and tuberculosis: applying the lessons of thioacetazone
por: Falzon, Dennis, et al.
Publicado: (2014)

WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry?
por: Jain, Nirmal Kumar
Publicado: (2021)

Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2020)

Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union
por: van der Werf, Marieke J., et al.
Publicado: (2017)

High success and low recurrence with shorter treatment regimen for multidrug-resistant TB in Nepal
por: Koirala, S., et al.
Publicado: (2021)

At Long Last: Short, All-Oral Regimens for Multidrug-Resistant Tuberculosis in the United States
por: Sinha, Pranay, et al.
Publicado: (2023)

Modernizing Surveillance of Antituberculosis Drug Resistance: From Special Surveys to Routine Testing
por: Zignol, Matteo, et al.
Publicado: (2011)

Modelling the effect of short-course multidrug-resistant tuberculosis treatment in Karakalpakstan, Uzbekistan
por: Trauer, James M., et al.
Publicado: (2016)

Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis
por: Fofana, Mariam O., et al.
Publicado: (2014)

What’s Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis
por: Campbell, Jonathon R., et al.
Publicado: (2019)

High Levels of Treatment Success and Zero Relapse in Multidrug-Resistant Tuberculosis Patients Receiving a Levofloxacin-Based Shorter Treatment Regimen in Vietnam
por: Anh, Le T. N., et al.
Publicado: (2020)

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2023)

Capturing patient-reported and quality of life outcomes with use of shorter regimens for drug-resistant tuberculosis: mixed-methods substudy protocol, TB PRACTECAL-PRO
por: Stringer, Beverley, et al.
Publicado: (2021)

Magnitude and Impacts of Adverse Events of Injectable Containing Shorter Regimen in Programmatic Management of Multi-Drug Resistant Tuberculosis in Ethiopia: A Retrospective Cohort Study
por: Achalu, Daniel Legese, et al.
Publicado: (2023)

Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies
por: Alipanah, Narges, et al.
Publicado: (2018)

Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis
por: Vesga, Juan F., et al.
Publicado: (2022)

Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis
por: Kwon, Yong-Soo
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_75uqp6fer8hbqtto70amj2vrl0